NVAX Rebound WaveNVAX is looking to complete its correction wave pattern. Its holding above its moving averages at the top of the flagging range. It is close to the apex of the range looking to breakout. Looking this to run to 250 area.
NVV1 trade ideas
Set alert and wait. Nvax pennant Forming a pennant on daily chart. Johnson &Johnson's misfortune still wasn't enough to push through. Channel resistance intersects with fib resistance at 204.
Public info says vaccine approval expected for UK and US use this quarter.
Entry 204 or pennant break out
targets (Green lines) are fib resistance
$NVAX getting ready for break out Price has been respecting the daily uptrend on this pennant pattern formed on the daily time frame. The pattern its formed suggest a break out will likely follow. With the president trying to get everyone vaccinated as soon as possible im bullish on the catalyst. The daily RSI is in a neutral position, and the stochastic looks to be shifting towards the upside. On the 4hr and 1 hr the stochastic are showing bullish potential with no crosses in the moving averages. I charted this on the daily so ill be looking to buy at least 30 days out. Not much more to say here other than buy the dip.
lmk what y'all think about the TA
$NVAX Novavax Reverses off Major Support
After a 20% drop this morning the stock staged quiet a nice recovery after hitting multiple supports=
- The Fibonacci Golden pocket
- The ascending trendline
- The 100MA.
resulting in a 10% reversal trade.
Lets see what Fridays brings and the possibility for a bounce in the Nasdaq and Biotech sector.
ABC BullishNVAX pulled back, found a large gap, filled it and appears to want to move upward.
Possible stop below C or last pivot low
Possible Targets 2 432.5 to 500
Not a recommendation.
Can be volatile
ABC BullishNVAX pulled back, found a large gap, filled it and appears to want to move upward.
Possible stop below C or last pivot low
Possible Targets 2 432.5 to 500
Not a recommendation.
Can be volatile
NVAX Round upNVAX gapped down today right into its moving average support. I believe its going to finish its rounding pattern and exceed the highs from yesterday. The 50 sma is at support as well at the 201 mark. I was able to enter at 214, but couldn't post this idea right away. Target is at the top of rounding formation at 245
Nvax ReversalBroke above 217.88 (yellow line) heavy resistance premarket.
Good news has been coming out of this company as far as vaccine trials.
American FDA approval could come around may and with that AstraZeneca nightmare in Germany, early Europe approval could be in play.
stop loss at 217
Targets are Fibonacci (Greenlines)
Novavax on to new highsNVAX could not even break and retest the old Resistance from August, it also formed a nice setup, where the break was also a break of the downtrendline at the same time.
Todays Session retested both, now forming a double support, which could allow us some decent gains...
Trading Novavax after BreakoutNVAX jumped roughly 20% overnight after announcing 96.4% efficacy against the disease caused by the original COVID-19 strain. This single move caused the shares to break out from the downside channel and crack through the 50-day and 20-day moving averages. With this important resistance zone left behind, the shares are poised to open just above the yearly Fibonacci R2 and monthly S1 levels ($216 and $213; RY2 and SM1 lines on the chart).
The question is whether the bulls can push the stock even higher today. Personally, I do not rule out that such a powerful upside gap - amid broader market concerns - could trigger some profit taking. Therefore, I will be watching to see if the stock can hold the RY2 / SM1 zone. If this happens, we can see NVAX approaching the $250 zone followed by the monthly pivot level ($258, PM) near-term.
On the downside , a break below RY2 / SM1 will put the 20- and 50-day moving averages to the test. An even more bearish scenario involves retesting recent diagonal resistance and potential gap filling at $188. This zone, however, should serve as very strong support, where we will definitely see buybacks.
Novavax +50% The final analysis of the U.K. trial showed that the vaccine was 96.4% effective against "mild, moderate, and severe disease caused by the original COVID-19 strain.
Vaccine efficacy was 86.3% against the fast-spreading U.K. variant (B.1.1.7/501Y.V1). Overall vaccine efficacy was 89.7%.
Comparison chart $OCGN with $NVAX Tribune News Service
New Delhi, March 10
India’s indigenous COVID-19 vaccine COVAXIN is no longer to be used in clinical trial mode and has got the nod of national experts to be used under the normal restricted emergency use authorisation route, just like the Serum Institute manufactured Covishield.
The move entails a huge boost to the indigenous Covid vaccine sector and the ICMR and Bharat Biotech, the joint developers of COVAXIN.
The restricted emergency use authorisation to COVAXIN had been held up in early January as the vaccine’s phase 3 efficacy data was unavailable till then and its efficiency was yet to be established though the vaccine was safe and immunogenic in early phase 1 and 2 trials.
The drug regulator had at that time approved the use of COVAXIN in clinical trial mode until efficacy data came.
With Bharat Biotech presenting interim phase 3 data showing 81 per cent efficacy for COVAXIN and Lancet also declaring the vaccine safe and immunogenic with minimum side effects based on phase 2 trial data published yesterday, the subject experts at the Central Drug Standard Control Organisation today reviewed COVAXIN data for two hours and recommended that the vaccine be brought out of the use in clinical trial mode and placed in the category of restricted emergency use.
This means beneficiaries of COVAXIN would not need to be followed up closely after administration of the jab, something that was mandatory when the vaccine was permitted for use in clinical trial mode.
COVAXIN export will also get a boost with the move.
I reopened my NVAX short with <120 targetAfter liquidating my 175 puts yesterday, as described in the linked idea,
I am shorting it again via 3/12 120 puts. My bet will win if it has another run down next week.
As a reminder, I don't do Yolo's, so my strategy assumes that I am going to be wrong and lose money most of the time.
I am careful with the size of my bets and this one is no exception.
My lucky 14x profit on NVAX and why I am still ready to short itI covered my shorts on NVX once 150 was reached. See my linked idea.
I did this trade with puts. Which were mostly crazy expensive at the time, but I was able to get 175 3/05 Puts for about $1.50 a couple of weeks ago.
I sold them today for an average price of 20.5, which gives this trade a 14x result.
Looking at the chart and at fundamentals, I will be looking for a short reentry. Let's see if I get a chance! There seems to be good support at 70-80 level.
Closing Nvax Shortcould still close gap, but hit most of the move, staying neutral, looking for long entry
NVAX Just Completed its Head & Shoulders. Target: $150ishAlright, just look at the chart. Chances are this is a major trend reversal.
2021 Actual Trade: NVAX +122% ProfitsNVAX provides desirable sideway patterns both from September-November 2020 and December-January 2021 so it gave us a chance to study NVAX from technical and fundamental perspectives.
After we accumulated twice in January 2021, NVAX was discovered and shot to the sky. We took a quick profit first. Then, COVID-19 began to decline, which caused NVAX to slow down also. We decided to close it completely. The highest point we got from NVAX was +122% profits.
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100..
Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
